EUR-1008 (APT-1008)

Phase 3Small molecule

FForest Laboratories

EUR-1008 (APT-1008) is one of 66 small molecule programs targeting Chronic Pancreatitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic PancreatitisActive, not recruiting

Cystic FibrosisActive, not recruiting

Chronic PancreatitisPhase 3

Active, not recruiting

Cystic FibrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

EUR-1008 (APT-1008)

FForest Laboratories

Phase 3

3 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 9

Capromorelin

UUniversity of Aarhus

Preclinical

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis3 trials

Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Completed·FForest Laboratories·Phase 3·NCT01641393·96 enrolled

Study to Evaluate the Safety and Efficacy of EUR-1008 (APT-1008) Pancreatic Enzyme Product in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Completed·FForest Laboratories·Phase 3·NCT00297167·34 enrolled

Study of Pancreatic Enzyme Product in Pediatric Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency

Completed·FForest Laboratories·Phase 3·NCT00981214·19 enrolled

Chronic Pancreatitis1 trial

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Completed·FForest Laboratories·Phase 3·NCT00788593·82 enrolled

Infants1 trial

A Study to Evaluate the Mode of Administration and Safety of EUR-1008 (APT-1008) in Infants 1 to 12 Months of Age

Completed·FForest Laboratories·Phase 4·NCT01100606·15 enrolled

Unspecified1 trial

PR-018: An Open-Label, Safety Extension of Study PR-011

Completed·FForest Laboratories·Phase 4·NCT01131507·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for EUR-1008 (APT-1008). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EUR-1008 (APT-1008) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EUR-1008 (APT-1008). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FForest Laboratories

EUR-1008 (APT-1008)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis3 trials

Chronic Pancreatitis1 trial

Infants1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News